Introduction {#s0001}
============

Sulfonamides constitute an important class of drugs. They possess various types of pharmacological activities such as antibacterial, high-ceiling diuretic, hypoglycemic, antithyroid, anti-inflammatory and antiglaucoma[@CIT0001]. Moreover, numerous sulfonamides were found to act as tyrosinase and urease inhibitors[@CIT0010].

Tyrosinase (EC 1.14.18.1) is a multifunctional copper containing enzyme from oxidase family, widely distributed in animals, plants and microorganisms[@CIT0013]. It catalyzes two distinct reactions of melanin synthesis, the hydroxylation of [l]{.smallcaps}-tyrosine by monophenolase action and the oxidation of [l]{.smallcaps}-DOPA (3,4-dihydroxyphenylalanine) to o-dopaquinone[@CIT0014]. Tyrosinase catalyzes melanin biosynthesis which plays a crucial role in protecting the skin from solar radiations. Melanin can serve as a photoprotector and is responsible for the pigmentation and color patterns of mammalian skin. It has been reported that effective tyrosinase inhibitors could ameliorate skin hyperpigmentation, neurodegenerative diseases, and could potentially improve cancer remedies[@CIT0015] ^,^ [@CIT0016]. However, when exposed to excessive ultraviolet light, melanin produced in excess causes various skin disorders[@CIT0017].

Urease (EC 3.5.1.5) is a nickel containing enzyme that catalyzes the hydrolysis of urea to ammonia and carbon dioxide or carbamate by at least 10[@CIT0014] over the spontaneous reaction[@CIT0018]. It is of our interest to focus on the discovery of novel urease inhibitors as it is already known that these compounds play a crucial part in the therapies both human and plants disorders. In agriculture, high urease activity during urea fertilization causes significant environmental and economic problems by releasing abnormally large amounts of ammonia into the atmosphere[@CIT0019] ^,^ [@CIT0020]. Moreover, it contributes to the development of peptic ulcers, pyelonephritis, kidney stones, hepatic encephalopathy, hepatic coma urolithiasis and urinary catheter encrustation[@CIT0021].

Our current work continuing our interest in the synthesis of new sulfonamide derivatives of pyrazolo\[4,3-*e*\]\[1,2,4\]triazine as new inhibitors of tyrosinase and urease enzymes. The synthesis pathway leading to the title compounds is depicted in [Scheme 1](#SCH0001){ref-type="scheme"}.

![Synthetic pathway to the sulfonamides **8a--i**. Reagents and conditions: (a) CH~3~CH~2~NO~2~, KOH, DMSO, 2 h, 80--86%; (b) Na~2~S~2~O~4~, H~2~O/dioxane, rt, 12 h, 55--65%; (c) CH~3~NH--NH~2~, PTSA, EtOH, rt, 1 h, 50--55%; (d) method A: 10% HCl, EtOH, reflux, 1 h, 58--61%; method B: PTSA, 140 °C, 1 min, 61%; (e) ethoxyphenylboronic acid, Pd(PPh~3~)~4~, CuMeSal, THF, Ar, reflux, overnight, 75--80%; (f); ClSO~3~H, 0 °C to rt, 2 h, 75--95%; (g) appropriate amine, anhydrous MeCN, rt, overnight, 72--93%.](IENZ_A_1238362_SCH0001){#SCH0001}

Experimental {#s0002}
============

Chemistry {#s0003}
---------

### Materials and methods {#s0004}

All chemicals used were of reagent grade quality and were used as received without any further purification and were obtained from Sigma-Aldrich. Melting points were determined on a Mel-Temp apparatus and are uncorrected. ^1^H- and ^13^C-NMR spectra were recorded on a Varian spectrometer (400 MHz for ^1^H and 100 MHz for ^13^C). The chemical shift values are expressed in ppm (part per million) with TMS as internal reference. The relative integrals of peak areas agreed with those expected for the assigned structures. Molecular weight of final compounds were assessed by electrospray ionization mass spectrometry (ESI/MS) on a Agilent Technologies 6538 UHD Accurate Mass Q-TOF LC/MS. Elemental compositions are within ±0.4% of the calculated values. For preparation and spectroscopic data of compounds **2--7** and **8a**, **8b**, **8 h**, **8i** see literature[@CIT0022].

Synthesis of sulfonamides 8a--j {#s0005}
-------------------------------

A mixture of sulfonyl chloride **7** (100 mg, 0.29 mmol) and amine (100 mg, 1 mmol) in anhydrous acetonitrile (5 mL) was stirred overnight at room temperature, and then the reaction mixture was concentrated *in vacuo* to afford the crude sulfonamide, as a yellow solid[@CIT0002] ^,^ [@CIT0024]. The residue was purified on silica gel using a mixture of CH~2~Cl~2~:EtOH (25:1) as eluent to give the titled compounds as a yellow solid.

(*S*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(1-hydroxy-propan-2-yl)benzenesulfonamide (8a) {#s0006}
================================================================================================================================

Yield 92%, mp 132--136 °C. ^1^H-NMR (CDCl~3~) δ: 1.09 (d, 3H, *J* = 6.4 Hz), 1.35 (t, 3H, *J* = 6.8 Hz), 2.63 (bs, 1H, OH, exchanged with D~2~0), 2.70 (s, 3H), 3.39--3.46 (m, 2H), 3.56 (d, 1H, *J* = 7.6 Hz), 4.19 (q, 2H, *J* = 6.4 Hz), 4.31 (s, 3H), 5.11 (d, 1H, *J* = 6.0 Hz, NH, exchanged with D~2~O), 7.14 (d, 1H, *J* = 9.2 Hz), 7.98 (dd, 1H, *J* ~1 ~=~ ~8.4 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.28 (d, 1H, *J* = 2.4 Hz).^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 17.9, 34.8, 51.5, 64.9, 65.9, 112.7, 126.9, 130.4, 131.3, 132.1, 134.5, 142.2, 146.7, 158.4, 160.4. HRMS (ESI, *m/z*) calcd. for C~17~H~22~N~6~O~4~S \[M+\] 406.1423. Found \[M+\] 406.1427. Anal. calcd. for C~17~H~22~N~6~O~4~S: C, 50.23; H, 5.46; N, 20.68. Found: C, 50.00; H, 5.49; N, 20.50.

(*R*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(1-hydroxy-propan-2-yl)benzenesulfonamide (8b) {#s0007}
================================================================================================================================

Yield 89%, mp 132--136 °C. ^1^H-NMR (CDCl~3~) δ: 1.09 (d, 3H, *J* = 6.4 Hz), 1.34 (t, 3H, *J* = 6.8 Hz), 2.69 (s, 3H), 2.84 (bs, 1H, OH, exchanged with D~2~0), 3.38--3.45 (m, 2H), 3.55 (d, 1H, *J* = 7.6 Hz), 4.18 (q, 2H, *J* = 6.4 Hz), 4.32 (s, 3H), 5.24 (d, 1H, *J* = 6.4 Hz, NH, exchanged with D~2~O), 7.13 (d, 1H, *J* = 8.8 Hz), 7.98 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.27 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 17.8, 34.8, 51.5, 64.9, 65.9, 112.7, 126.9, 130.4, 131.3, 132.1, 134.5, 142.1, 146.7, 158.4, 160.4. HRMS (ESI, *m/z*) calcd. for C~17~H~22~N~6~O~4~S \[M+\] 406.1423. Found \[M+\] 406.1426. Anal. calcd. for C~17~H~22~N~6~O~4~S: C, 50.23; H, 5.46; N, 20.68. Found: C, 49.89; H, 5.49; N, 20.55.

(*S*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide (8c) {#s0008}
=======================================================================================================================================

Yield 91%, mp 115--120 °C. ^1^H-NMR (CDCl~3~) δ: 0.83 (dd, 6H, *J* ~1 ~=~ ~6.8 Hz, *J* ~2 ~=~ ~2.8 Hz), 1.34 (t, 3H, *J* = 6.8 Hz), 1.82 (s, 1H, *J* = 6.8 Hz), 2.69 (s, 3H), 3.07--3.11 (m, 1H), 3.52--3.55 (m, 2H), 4.17 (q, 2H, *J* = 6.8 Hz), 4.32 (s, 3H), 5.23 (d, 1H, *J* = 8.4 Hz, NH, exchanged with D~2~O), 7.11 (d, 1H, *J* = 8.8 Hz), 7.96 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.8 Hz), 8.27 (d, 1H, *J* = 2.8 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 18.5, 19.1, 29.6, 34.8, 60.9, 62.5, 64.9, 112.6, 126.7, 130.4, 131.4, 132.4, 134.5, 142.1, 146.6, 158.4, 160.3. HRMS (ESI, *m/z*) calcd. for C~19~H~26~N~6~O~4~S \[M+\] 434.1736 Found \[M+\] 434.1741. Anal. calcd. for C~19~H~26~N~6~O~4~S: C, 52.51; H, 6.03; N, 19.35. Found: C, 52.18; H, 6.06; N, 19.22.

(*R*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide (8d) {#s0009}
=======================================================================================================================================

Yield 72%, mp 115--120 °C. ^1^H-NMR (CDCl~3~) δ: 0.84 (dd, 6H, *J* ~1 ~=~ ~6.8 Hz, *J* ~2 ~=~ ~3.6 Hz), 1.35 (t, 3H, *J* = 6.8 Hz), 1.82 (s, 1H, *J* = 6.8 Hz), 2.70 (s, 3H), 3.08--3.11 (m, 1H), 3.50--3.58 (m, 2H), 4.18 (q, 2H, *J* = 6.8 Hz), 4.32 (s, 3H), 5.16 (d, 1H, *J* = 8.8 Hz, NH, exchanged with D~2~O), 7.11 (d, 1H, *J* = 8.8 Hz), 7.96 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.28 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 18.5, 19.1, 29.6, 34.8, 60.9, 62.5, 64.9, 112.6, 126.8, 130.4, 131.4, 132.4, 134.5, 142.2, 146.7, 158.4, 160.3. HRMS (ESI, *m/z*) calcd. for C~19~H~26~N~6~O~4~S \[M+\] 434.1736 Found \[M+\] 434.1741. Anal. calcd. for C~19~H~26~N~6~O~4~S: C, 52.51; H, 6.03; N, 19.35. Found: C, 52.18; H, 6.10; N, 19.15.

(*S*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(2-hydroxy-propyl)-benzenesulfonamide (8e) {#s0010}
============================================================================================================================

Yield 90%, mp 132--135 °C. ^1^H-NMR (CDCl~3~) δ: 1.13 (d, 3H, *J* = 6.4 Hz), 1.34 (t, 3H, *J* = 6.8 Hz), 2.67 (bs, 1H, OH exchanged with D~2~O), 2.70 (s, 3H), 2.79--2.86 (m, 1H), 3.05--3.11 (m, 1H), 3.86--3.94 (m, 1H), 4.17 (q, 2H, *J* = 6.8 Hz), 4.32 (s, 3H), 5.35 (t, 1H, *J* = 6.0 Hz, NH, exchanged with D~2~O), 7.13 (d, 1H, *J* = 8.8 Hz), 7.95 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.24 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 20.5, 34.8, 50.1, 64.9, 66.3, 112.8, 127.0, 130.4, 131.2, 131.3, 134.5, 142.1, 146.7, 158.4, 160.4. HRMS (ESI, *m/z*) calcd. for C~17~H~22~N~6~O~4~S \[M+\] 406.1423 Found \[M+\] 406.1426. Anal. calcd. for C~17~H~22~N~6~O~4~S: C, 50.23; H, 5.46; N, 20.68. Found: C, 49.89; H, 5.52; N, 20.53.

(*R*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(2-hydroxy-propyl)-benzenesulfonamide (8f) {#s0011}
============================================================================================================================

Yield 90%, mp 132--135 °C. ^1^H-NMR (CDCl~3~) δ: 1.13 (d, 3H, *J* = 6.4 Hz), 1.34 (t, 3H, *J* = 6.8 Hz), 2.59 (bs, 1H, OH exchanged with D~2~O), 2.70 (s, 3H), 2.79--2.86 (m, 1H), 3.05--3.11 (m, 1H), 3.86--3.94 (m, 1H), 4.18 (q, 2H, *J* = 6.8 Hz), 4.32 (s, 3H), 5.29 (bs, 1H, NH, exchanged with D~2~O), 7.13 (d, 1H, *J* = 8.8 Hz), 7.95 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.24 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 20.6, 34.8, 50.1, 64.9, 66.4, 112.8, 127.0, 130.4, 131.3, 131.3, 134.5, 142.1, 146.8, 158.4, 160.5. HRMS (ESI, *m/z*) calcd. for C~17~H~22~N~6~O~4~S \[M+\] 406.1423 Found \[M+\] 406.1425. Anal. calcd. for C~17~H~22~N~6~O~4~S: C, 50.23; H, 5.46; N, 20.68. Found: C, 49.91; H, 5.56; N, 20.48.

(*S*)-*N*-(2,3-dihydroxypropyl)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxybenzenesulfonamide (8g) {#s0012}
==============================================================================================================================

Yield 78%, mp 117--121 °C. ^1^H-NMR (MeOH-d~4~) δ: 1.29--1.33 (m, 5H), 2.68 (s, 3H), 2.85--2.90 (m, 1H), 3.04--3.08 (m, 1H), 3.49 (t, 2H, *J* = 6.0 Hz), 3.67 (m, 1H), 4.22 (q, 2H, *J* = 6.8 Hz), 4.31 (s, 3H), 7.36 (d, 1H, *J* = 8.8 Hz), 8.01 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.17 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (DMSO) δ: 11.1, 14.7, 35.0, 46.4, 63.9, 65.0, 70.7, 113.9, 127.1, 130.4, 130.6, 132.4, 134.4, 141.5, 147.0, 158.4, 159.9. HRMS (ESI, *m/z*) calcd. for C~17~H~22~N~6~O~5~S \[M+\] 422.1372 Found \[M+\] 406.1375. Anal. calcd. for C~17~H~22~N~6~O~5~S: C, 48.33; H, 5.25; N, 19.90. Found: C, 48.05; H, 5.29; N, 19.77.

(*R*)-*N*-(2,3-dihydroxypropyl)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxybenzenesulfonamide (8h) {#s0013}
==============================================================================================================================

Yield 79%, mp 117--121 °C. ^1^H-NMR (MeOH-d~4~) δ: 1.29--1.33 (m, 5H), 2.69 (s, 3H), 2.85--2.90 (m, 1H), 3.04--3.08 (m, 1H), 3.49 (t, 2H, *J* = 6.0 Hz), 3.66 (m, 1H), 4.22 (q, 2H, *J* = 6.8 Hz), 4.31 (s, 3H), 7.36 (d, 1H, *J* = 8.8 Hz), 8.01 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.17 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (MeOH-d~4~) δ: 20.2, 23.8, 44.1, 55.5, 72.9, 74.1, 79.8, 123.0, 136.1, 139.4, 139.6, 141.5, 143.4, 150.5, 156.1, 167.4, 169.0. HRMS (ESI, *m/z*) calcd. for C~17~H~22~N~6~O~5~S \[M+\] 422.1372 Found \[M+\] 406.1376. Anal. calcd. for C~17~H~22~N~6~O~5~S: C, 48.33; H, 5.25; N, 19.89. Found: C, 48.14; H, 5.35; N, 19.77.

(*S*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(1-hydroxy-4-methylpentan-2-yl)benzenesulfonamide (8i) {#s0014}
========================================================================================================================================

Yield 91%, mp 112--116 °C. ^1^H-NMR (CDCl~3~) δ: 0.73 (d, 3H, *J* = 6.8 Hz), 0.81 (d, 3H, *J* = 6.8 Hz), 1.27--1.29 (m, 1H), 1.32--1.38 (m, 4H), 1.56--1.60 (m, 1H), 2.70 (s, 3H), 3.36--3.39 (m, 1H), 3.41--3.45 (m, 1H), 3.54--3.57 (m, 1H), 4.19 (q, 2H, *J* = 6.8 Hz), 4.33 (s, 3H), 5.03 (d, 1H, *J* = 8.0 Hz, NH, exchanged with D~2~O), 7.13 (d, 1H, J = 8.8 Hz), 7.98 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.30 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 21.9, 22.7, 24.3, 34.8, 41.1, 53.8, 64.7, 64.9, 112.7, 127.0, 130.4, 131.4, 132.4, 134.5, 142.2, 146.7, 158.3, 160.4. HRMS (ESI, *m/z*) calcd. for C~20~H~28~N~6~O~4~S \[M+\] 448.1893 Found \[M+\] 448.1899. Anal. calcd. for C~20~H~28~N~6~O~4~S: C, 53.55; H, 6.29; N, 18.74. Found: C, 53.33; H, 6.39; N, 18.63.

(*R*)-3-(1,3-dimethyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazin-5-yl)-4-ethoxy-*N*-(1-hydroxy-4-methylpentan-2-yl)benzenesulfonamide (8j) {#s0015}
========================================================================================================================================

Yield 93%, mp 112--116 °C. ^1^H-NMR (CDCl~3~) δ: 0.70 (d, 3H, *J* = 6.4 Hz), 0.78 (d, 3H, *J* = 6.4 Hz), 1.25--1.27 (m, 1H), 1.31--1.36 (m, 4H), 1.54--1.60 (m, 1H), 2.67 (s, 3H), 3.10 (bs, 1H, OH), 3.32--3.42 (m, 2H), 3.52--3.57 (m, 1H), 4.18 (q, 2H, *J* = 6.8 Hz), 4.30 (s, 3H), 5.34 (d, 1H, *J* = 8.0 Hz, NH, exchanged with D~2~O), 7.11 (d, 1H, *J* = 8.8 Hz), 7.96 (dd, 1H, *J* ~1 ~=~ ~8.8 Hz, *J* ~2 ~=~ ~2.4 Hz), 8.27 (d, 1H, *J* = 2.4 Hz). ^13^C-NMR (CDCl~3~) δ: 11.0, 14.4, 21.9, 22.7, 24.3, 34.8, 41.1, 53.8, 64.7, 64.9, 112.7, 127.0, 130.4, 131.4, 132.4, 134.5, 142.2, 146.7, 158.3, 160.4. HRMS (ESI, *m/z*) calcd. for C~20~H~28~N~6~O~4~S \[M+\] 448.1893 Found \[M+\] 448.1894. Anal. calcd. for C~20~H~28~N~6~O~4~S: C, 53.55; H, 6.29; N, 18.74. Found: C, 53.21; H, 6.33; N, 18.59.

Pharmacology {#s0016}
------------

### Reagents {#s0017}

Mushroom tyrosinase (EC 1.14.18.1), urease from Jack bean (EC 3.5.1.5), [l]{.smallcaps}-DOPA (3,4-dihydroxyphenylalanine), Kojic acid, thio-urea, EDTA, sodium nitroprusside and active chloride, were purchased from Sigma (St. Louis, MO, USA). Stock solutions of the reducing substrates were prepared in phosphate buffer (20 mM, pH 6.8).

Mushroom tyrosinase inhibition assay {#s0018}
====================================

The mushroom tyrosinase (EC 1.14.18.1) (Sigma Chemical Co.) was used for *in vitro* bioassays as described previously with some modifications.[@CIT0025] ^,^ [@CIT0026] Briefly, 140 μL of phosphate buffer (20 mM, pH 6.8), 20 μL of mushroom tyrosinase (30 U/mL) and 20 μL of the inhibitor solution were placed in the wells of a 96-well micro plate. After pre-incubation for 10 min at room temperature, 20 μL of [l]{.smallcaps}-DOPA (3,4-dihydroxyphenylalanine) (0.85 mM) was added and the plate was further incubated at 25 °C for 20 min. Subsequently the absorbance of dopachrome was measured at 475 nm using a micro plate reader (OPTI~Max~, Tunable). Kojic acid was used as a reference inhibitor and for negative tyrosinase inhibitor phosphate buffer was used instead of the inhibitor solution. The extent of inhibition by the test compounds was expressed as the percentage of concentration necessary to achieve 50% inhibition (IC~50~). Each concentration was analyzed in three independent experiments run in triplicate. The IC~50~ values determined by the data analysis and graphing software Origin 8.6, 64-bit (OriginLab Corporation, Northampton, MA).

Urease inhibition assay {#s0019}
=======================

The urease activity was determined by measuring amount of ammonia produced with indophenols method described by Weatherburn[@CIT0027]. The reaction mixtures, comprising 20 μL of enzyme (Jack bean urease, 5 U/mL) and 20 μL of test compounds in 50 μL buffer (100 mM urea, 0.01 M K~2~HPO~4~, 1 mM EDTA and 0.01 M LiCl~2~, pH 8.2), were incubated for 30 min at 37 °C in 96-well plate. Briefly, 50 μL each of phenol reagents (1%, w/v phenol and 0.005%, w/v sodium nitroprusside) and 50 μL of alkali reagent (0.5%, w/v NaOH and 0.1% active chloride NaOCl) were added to each well. The absorbance at 625 nm was measured after 10 min, using a microplate reader (OPTI~Max~, Tunable). All reactions were performed in triplicate. The urease inhibition activities were calculated according to the following formula: $$\text{Urease\ inhibition\ activity}\left( \% \right) = \left( {OD}_{control} - {OD}_{sample} \times 100 \right)/{OD}_{control}$$ Where OD~control~ and OD~sample~ represents the optical densities in the absence and presence of sample, respectively. Thiourea was used as the standard inhibitor for urease.

Kinetic study {#s0020}
=============

Lineweaver--Burk plots of 1/absorbance versus 1/[l]{.smallcaps}-DOPA and 1/absorbance versus 1/Urea were used to determine the type of enzyme inhibition. A series of experiments were performed to determine the inhibition kinetics by following method[@CIT0018] ^,^ [@CIT0028] ^,^ [@CIT0029]. Different inhibitor concentrations of compound **8b** with 0, 15, 30, 61, 123 and 247 μM, **8j** with 0, 14, 28 and 55.8 μM, respectively were used in case of mushroom tyrosinase inhibition. Substrate [l]{.smallcaps}-DOPA concentration was between 0.062 and 2 mM in all tyrosinase kinetic study. Pre-incubation and measurement time was the same as discussed in mushroom tyrosinase inhibition assay protocol. Maximal initial velocity was determined from initial linear portion of absorbance up to five minutes after addition of enzyme at a 30 s interval. The inhibition type on the enzyme was assayed by Lineweaver--Burk plots of inverse of velocities (1/*V*) versus inverse of substrate concentration 1/\[S\] mM ^−^ ^1^, and the inhibition constant *Ki* was determined by two methods, by secondary replot of 1/*V* (y-intercept of Lineweaver--Burk plot) versus inhibitor concentrations and by Dixon plot of inverse of velocities (1/*V*) versus inhibitor concentrations.

Urease inhibition was measured by varying the concentration of urea in the presence of different concentrations (0, 0.125, 0.25 and 0.5 μM) of compound **8a.** Inhibitory constant (*Ki*) was determined as the intersection on the X-axis of the secondary replot of 1/*V* (y-intercept of Lineweaver--Burk plot) versus inhibitor concentrations and by Dixon plot of inverse of velocities (1/*V*) versus inhibitor concentrations. Briefly the urea concentration was changed from 3.12 to 100 mM for urease kinetics studies and remaining procedure was same as describes in urease inhibition assay protocol. Urease activity was determined by measuring ammonia production using the indophenol method as reported previously[@CIT0030]. The results (change in absorbance per min) were processed by using SoftMaxPro software(Molecular Devices Corporation Sunnyvale, CA) and a Dixon plot was constructed by plotting (1/*V*) versus inhibitor concentration \[I\].

Results and discussion {#s0021}
======================

Chemistry {#s0022}
---------

The synthesis of target sulfonamides **8a--i** was achieved by a convenient multiple procedure starting from 3-methylsulfanyl-1,2,4-triazine (**1**) as shown in [Scheme 1](#SCH0001){ref-type="scheme"}. Briefly, in the first step the reaction of **1** with nitroethane in KOH/DMSO mixture at room temperature gave appropriate oxime **2** as a main product[@CIT0022], which was readily transformed into ketone **3** in good yield[@CIT0023]. Compound **3** was subjected to the reaction with methylhydrazine in the presence of acidic media according to standard procedure to give suitable hydrazone **4** as key intermediate for the preparation of 1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazine derivative **5**. The hydrazone **4** could be converted into derivative **5** under conventional heating (10% HCl, EtOH, reflux, 1 h)[@CIT0031] or under solvent free reaction conditions according to our previous published procedure[@CIT0032]. Using Guillaumet and co-worker's method[@CIT0033] for the palladium-catalyzed cross-coupling reaction of 3-methylsulfanyl-1,2,4-triazine with boronic acid derivatives we have reacted 5-methylsulfanyl-1*H*-pyrazolo\[4,3-*e*\]\[1,2,4\]triazines **5** with 2-ethoxyphenylboronic acid in the presence of copper (I) 3-methylsalicylate to obtain derivative **6** in excellent yield. Chlorosulfonylation reaction of compound **6** in neat chlorosulfonic acid at 0 °C proceeded smoothly and selectively at the 5'-position of the phenyl ring to give the desired product **7** in excellent yield. The chlorosulfonyl derivative **7** was readily coupled with appropriate pure enantiomeric amines in acetonitrile at room temperature to produce the final chiral sulfonamides **8a--i** in high yield.

Pharmacology {#s0023}
------------

### Effect of inhibitors on tyrosinase and urease {#s0024}

#### Tyrosinase assay {#s0025}

All chiral sulfonamides **8a--j** are structurally similar and showed comparable inhibitory effects on mushroom tyrosinase \[IC~50~ in the range of 27.9--40.17 μM\]. Weaker inhibitors were derivatives **8i** (IC~50 ~=~ ~40.17 μM), **8e** (IC~50 ~=~ ~39.75 μM), and **8c** (IC~50 ~=~ ~39.00 μM) with (*S*)-(+)-leucinol, (*S*)-(+)-1-amino-3-propanol and (*S*)-(+)-2-amino-3-methyl-1-butanol moieties in sulfonamide group. The most active inhibitor in the tested group was compound **8j** (IC~50 ~=~ ~27.90 μM) which contains (*R*)-(−)-leucinol substituent ([Table 1](#t0001){ref-type="table"}).

###### 

The inhibitory effects of compounds **8a--8j** on mushroom tyrosinase and urease.

  Compounds code   Mushroom tyrosinase IC~50~ (μM)   Urease IC~50~ (μM)
  ---------------- --------------------------------- ---------------------
  **8a**           38.46 ± 0.42                      **0.037**±**0.003**
  **8b**           **30.76**±**3.56**                0.084 ± 0.020
  **8c**           39.00 ± 1.34                      0.078 ± 0.020
  **8d**           38.15 ± 1.68                      0.064 ± 0.020
  **8e**           39.75 ± 1.92                      0.076 ± 0.007
  **8f**           34.72 ± 2.01                      **0.044**±**0.130**
  **8g**           36.49 ± 1.75                      0.063 ± 0.016
  **8h**           32.46 ± 1.87                      0.080 ± 0.014
  **8i**           40.17 ± 1.09                      **0.042**±**0.012**
  **8j**           **27.9**±**2.43**                 0.080 ± 0.015
  Kojic Acid       16.69 ± 2.8                       --
  Thio-Urea        --                                20.7 ± 0.45

Bolded values represent the most active derivatives.

Tyrosinase contains one binuclear copper complex in the catalytic center and the catechol hydroxyl groups of the substrate are suggested to be bound to the copper atoms during the enzymatic oxidation process. Phenolic hydroxyl groups are generally capable to coordinate copper atoms causing inhibition of the enzyme in competition to the catechol substrate. However, our previous study[@CIT0010] showed that inhibitors with NH group in the sulfonamide part (as piperazinyl, homopiperazinyl) are more active as they reduce the enzyme activity of tyrosinase to 29.5%--33.5%. It was suggested, that NH or free NH~2~ group are involved in the inhibition effect of tyrosinase activity. Our suggestion was confirmed by the activity of some inhibitor with two NH groups that reduced enzyme activity of tyrosinase to 20.2%.

The inhibition of the compound **8j** may arise with strong participation OH group due to its conformation. However, other tested derivatives with OH were only weak tyrosinase inhibitors. Therefore, we suggest that primary binding to one copper atom should be strengthened by additional interactions between the inhibitor e.g. π electrons of the ring and another copper atom or the amino acid residues of the enzyme's active site to accomplish the inhibition.

#### Urease assay {#s0026}

The synthesized pirazolotriazine-sulfonamides (**8a--j**) have been evaluated for their inhibitory effects on urease. All of the synthesized compounds showed better inhibitory activity with IC~50~ ranging from 0.037 to 0.084 μM than thiourea with IC~50~ of 20.7 μM. The structures of amino alcohols in sulfonamide group were varied to study their role in enzyme inhibitory activity. The excellent activity was shown by derivatives (**8a**) and (**8i**) with IC~50~ 0.037 and 0.042 μM, respectively. In case of compound (**8a**) the presence of 2-hydroxy-1-methyl ethaneamine moiety with S configuration at sulfonamide group has central importance in urease inhibitory activity in the group of tested derivatives. This moiety in compound **(8a**) is responsible for its most potent urease inhibitory activity. On the other hand, isomeric derivative (**8b**) with *R*-configuration in sulfonamide part showed the lowest activity in the group of obtained compounds although it exhibited higher urease inhibitory activity than standard thiourea.

### Mechanism underlying inhibitory effect of compounds (**8a**), (**8b**) and (**8j**) {#s0027}

Since **(8b)** and **(8j)** against mushroom tyrosinase and **(8a)** against urease enzyme were the most potent inhibitors, we therefore further study mechanism underlying their inhibitory effect. The kinetic studies of the enzyme by the Lineweaver--Burk plot of (1/*V*) versus 1/\[S\] in the presence of different concentrations of inhibitors **(8b), (8j)** and **(8a)** which gave a series of straight lines as shown in [Figures 1--3(a)](#F0001 F0002 F0003){ref-type="fig"}. Furthermore, inhibition constant (*Ki*) were determined to gain insightful pathway by secondary replots and Dixon plots as shown in [Figures 1--3(b,c)](#F0001 F0002 F0003){ref-type="fig"}. The results showed that compound **(8b)** behaved as a noncompetitive inhibitor ([Figure 1](#F0001){ref-type="fig"}), which means that it could combine with both the free enzyme and the enzyme-substrate complex. Thus, the interaction between **(8b)** and the enzyme was independent from the interaction between the substrate and the enzyme, and the inhibitor did not change substrate-enzyme affinity. With increasing concentrations, a series of lines was revealed with a common intercept on the 1/\[S\] axis, but with different slopes. On the other hand in Dixon plot **(8b)** was consistent with the characteristic patterns of noncompetitive inhibition with *Ki* value 40 μM and compound **(8j)** show mixed type inhibition with *Ki* value 20 μM as shown in [Figure 2(a,b](#F0002){ref-type="fig"}). In case of compound **(8a)** whose kinetic mechanism was studied against urease, by increasing the concentration of substrate (urea) gave family of straight lines, all of which intersected within the second quadrant. The analysis showed that *V* ~max~ decreased with increasing *K* ~m~ in the presence of increasing concentrations of **(8a)** This behavior of compound **(8a)**, indicated that it is a mixed type inhibitor with respect to the substrate urea with *Ki* value 0.01 μM as shown in [Figure 3(a--c)](#F0003){ref-type="fig"}. The results of inhibition type and inhibition constants are summarized in [Table 2](#t0002){ref-type="table"}.

![a) Lineweaver--Burk plots for the inhibition of mushroom tyrosinase in the presence of compound **(8b)**. Concentrations of **(8b)** were 0, 15, 30, 61, 123 and 247 μM, respectively. Substrate [l]{.smallcaps} *-*DOPA Concentrations were 0.125, 0.25, 0.5, 1 and 2 mM, respectively. b) The secondary replot of the Lineweaver--Burk plot, 1/V (y-intercept) of a) versus various concentrations of **(8b)**. c) The Dixon plot of the reciprocal of the initial velocities versus various concentrations of compound **(8b)** at fixed substrate concentration.](IENZ_A_1238362_F0001_C){#F0001}

![a) Lineweaver--Burk plots for the inhibition of mushroom tyrosinase in the presence of compound **(8j)**. Concentrations of **(8j)** were 0, 14, 28 and 55.8 μM, respectively. Substrate [l]{.smallcaps} *-*DOPA Concentrations were 0.062, 0.125, 0.25, 0.5, 1 and 2 mM, respectively. b) The Dixon plot of the reciprocal of initial velocities versus various concentrations of compound **(8j)** at fixed substrate concentration.](IENZ_A_1238362_F0002_C){#F0002}

![a) Double reciprocal Lineweaver--Burk plots for the inhibition of Jack bean urease in the presence of compound **(8a).** Concentrations of **(8a)** were 0, 0.125, 0.25 and 0.5 μM, respectively. Substrate urea concentrations were 3.12, 6.25, 12.5, 25, 50 and 100 mM, respectively. b) The secondary replot of the Lineweaver--Burk plot, 1/V (y-intercept) of a) versus various concentrations of **(8a)**. c) The Dixon plot of the reciprocal of the initial velocities versus various concentrations of compound **(8a)** at fixed substrate concentration.](IENZ_A_1238362_F0003_C){#F0003}

###### 

Inhibitory effect of compound **8b** and **8j** on mushroom tyrosinase activity and of **8a** on urease activity.

  Compound   Enzyme                           
  ---------- -------- ---------------- ------ ------------
  **8a**     --       --               0.01   Mixed type
  **8b**     40       Noncompetitive   --     --
  **8j**     20       Mixed type       --     --

*Ki* is enzyme inhibition constant.

-- is not determined.

Conclusions {#s0028}
===========

We have described facile and efficient method for the preparation of new chiral 1*H-*pyrazolo\[4,3-*e*\]\[1,2,4\]triazine sulfonamides from simple available starting materials. The sulfonamides (**8a--j**) have been synthesized to validate their role in tyrosine and urease inhibitory activity. The most potent inhibitory activity against tyrosinase was displayed by compounds (**8b**) and (**8j**) with IC~50~ 30.76 and 27.90 μM, respectively. All of the obtained derivatives showed higher urease inhibitory activity than the standard thiourea. The kinetic analysis exhibited that compounds (**8b**) is noncompetitive inhibitor while (**8j**) is a mixed type inhibitor of tyrosinase and (**8a**) is a mixed type inhibitor of urease. According to the systematic investigation it could be deduced that pyrazolotriazine sulfonamides are a promising urease inhibitors for treatment of the urease related diseases.
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